Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Dicerna Pharmaceuticals stock (DRNA)

Buy Dicerna Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Dicerna Pharmaceuticals is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Dicerna Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around $192.9 million.

Our top picks for where to buy Dicerna Pharmaceuticals stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Dicerna Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – DRNA. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Dicerna Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Dicerna Pharmaceuticals stock price (NASDAQ: DRNA)

Use our graph to track the performance of DRNA stocks over time.

Dicerna Pharmaceuticals shares at a glance

Information last updated 2022-02-20.
Latest market close$38.22
52-week range$0.00 - $0.00
50-day moving average $31.45
200-day moving average $28.97
Wall St. target price$38.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Is it a good time to buy Dicerna Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dicerna Pharmaceuticals price performance over time

Historical closes compared with the close of $38.22 from 2021-12-29

1 week (2024-07-03) N/A
1 month (2024-06-10) N/A
3 months (2024-04-10) N/A
6 months (2024-01-10) N/A
1 year (2023-07-10) N/A
2 years (2022-07-10) N/A
3 years (2021-07-14) 38.88
5 years (2019-07-12) 169.15%

Dicerna Pharmaceuticals financials

Revenue TTM $192.9 million
Gross profit TTM $-41,077,000
Return on assets TTM -10.43%
Return on equity TTM -95.22%
Profit margin -64.53%
Book value $1.38
Market Capitalization $3 billion

TTM: trailing 12 months

Dicerna Pharmaceuticals share dividends

We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.

Dicerna Pharmaceuticals share price volatility

Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

DRNA.US volatility(beta: 0.79)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 0.786. This would suggest that Dicerna Pharmaceuticals's shares are less volatile than average (for this exchange).

Dicerna Pharmaceuticals overview

Dicerna Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.

Frequently asked questions

What percentage of Dicerna Pharmaceuticals is owned by insiders or institutions?
Currently 7.434% of Dicerna Pharmaceuticals shares are held by insiders and 88.539% by institutions.
How many people work for Dicerna Pharmaceuticals?
Latest data suggests 302 work at Dicerna Pharmaceuticals.
When does the fiscal year end for Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals's fiscal year ends in December.
Where is Dicerna Pharmaceuticals based?
Dicerna Pharmaceuticals's address is: 75 Hayden Avenue, Lexington, MA, United States, 02421
What is Dicerna Pharmaceuticals's ISIN number?
Dicerna Pharmaceuticals's international securities identification number is: US2530311081
What is Dicerna Pharmaceuticals's CUSIP number?
Dicerna Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 253031108

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site